West Pharmaceutical Services (WST) EPS (Weighted Average and Diluted) (2009 - 2026)

West Pharmaceutical Services has disclosed EPS (Weighted Average and Diluted) across 18 years of filings, most recently posting $1.92 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $1.92, up 56.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.48 (up 17.43% YoY), and the FY2025 annual result was $6.79, up 1.49% from the prior year.
• EPS (Weighted Average and Diluted) came in at $1.92 for Q1 2026 at West Pharmaceutical Services, up from $1.82 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.48 in Q2 2022 to a low of $1.23 in Q1 2025.
• The 5-year median for EPS (Weighted Average and Diluted) is $1.83 (2023), against an average of $1.82.
• Across the five-year window, EPS (Weighted Average and Diluted) plunged 31.17% in 2022 and soared 56.1% in 2026, its largest moves.
• West Pharmaceutical Services' EPS (Weighted Average and Diluted) stood at $1.37 in 2022, then jumped by 33.58% to $1.83 in 2023, then retreated by 2.73% to $1.78 in 2024, then grew by 2.25% to $1.82 in 2025, then advanced by 5.49% to $1.92 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $1.92 (Q1 2026), $1.82 (Q4 2025), and $1.92 (Q3 2025), per Business Quant data.